Generated by AI
NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services. The company provides a broad menu of laboratory solutions across the cancer care continuum, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, and pathology support. Its services are used by oncologists, pathologists, hospitals, academic medical centers, and pharmaceutical companies to help characterize disease, guide treatment decisions, and support clinical research and drug development. NeoGenomics operates a network of cancer-focused laboratories in the United States and the United Kingdom, with business operations organized around Clinical Services and Advanced Diagnostics. Headquartered in Fort Myers, Florida, NeoGenomics plays a specialized role in precision medicine by delivering laboratory data and expert interpretation for cancer diagnosis and care.
Website9490 NeoGenomics Way
Fort Myers, FL, 33912
United States
The latest articles about NEO.
NeoGenomics (NEO) just delivered third quarter 2026 results that topped expectations, with double digit year over year revenue growth, improved adjusted earnings guidance, and a planned CEO transition that reshapes the leadership picture. NeoGenomics’ latest earnings surprise has arrived after a powerful run, with the share price delivering a 52.98% year to date share price return and a 75.00% total shareholder return over one year, even though the 5 year total shareholder return is still...
Summary of Oct 15's posts. Generated by AI.
Summary of Aug 29's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Investors talking about NEO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.